Details

A time series analysis approach to quantify change in antibiotic resistance and antibiotic consumption during COVID-19 epidemics : a multicentre cross-national ecological study on behalf of QUantifying change in Antibiotic Resistance, ANTibiotic use, and INfection control during COVID-19 Epidemics study project
ID Meschiari, Marianna (Author), ID Medioli, Filippo (Author), ID Pirš, Mateja (Author), ID Beović, Bojana (Author), et al.

.pdfPDF - Presentation file, Download (6,00 MB)
MD5: 3379A571DDF89D7AC3B81D48F9511380
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S1198743X25002964 This link opens in a new window

Abstract
Objectives: We aimed to assess the impact of COVID-19 on antibiotic consumption (AMC) and antimicrobial resistance (AMR) in the new epidemiological scenario from a cross-national perspective. Methods: A quasi-experimental retrospective multicentre ecological study was conducted to explore the impact of COVID-19 on AMC and AMR using routinely generated retrospective time series data. This study included nine Healthcare University Hospitals from Europe and Israel on behalf QUantifying change in Antibiotic Resistance, ANTibiotic use, and INfection control during COVID-19 Epidemics project. Total effects were defined as the difference between the pre-COVID-19 period (ranging from January 2015 or January 2016 to February 2020) and during the COVID-19 pandemic period (March 2020 to July 2021 or December 2021). The outcomes were incidence density (ID) of carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Klebsiella pneumoniae, extended-spectrum beta-lactamase-producing Escherichia coli, vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus, carbapenem-resistant Pseudomonas aeruginosa and Clostridioides difficile, as monthly isolates per 1000 patient days and the monthly AMC ranked according to the Access, Watch, and Reserve WHO classification system. Results: We assessed 15.9 million total hospital bed days, 315 736 COVID-19 bed days, 52 557 monthly bacterial isolates, and 461 739 monthly antimicrobial defined daily doses. The COVID-19 pandemic had a significant impact on the consumption of overall hospital antibiotics combined in all centres except two. Prescriptions for piperacillin/tazobactam, glycopeptides, and ceftazidime/avibactam increased, whereas third-generation cephalosporins, macrolides, and fluoroquinolones returned to pre-pandemic levels after an initial surge, in all centres. A positive relationship between the pandemic intensity and VRE ID was observed in 6 of 9 (66%) centres followed by methicillin-resistant S. aureus-ID and carbapenemresistant P. aeruginosa-ID 3 of 4 (44%) for both. A negative relationship was found for extendedspectrum beta-lactamase-producing E. coli ID. Discussion: The COVID-19 pandemic was associated with higher usage of broad-spectrum antibiotics and higher incidence of multidrug-resistant bacteria, with great variability by countries. These results could support international action plans that embed AMR as a priority in the post-COVID-19 era.

Language:English
Keywords:antibiotic consumption, antimicrobial resistance, COVID-19, multicentre, multi-drug resistant organisms, non-linear time series, thresholds
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:Str. 1500-1509
Numbering:Vol. 31, iss. 9
PID:20.500.12556/RUL-181457 This link opens in a new window
UDC:616.9
ISSN on article:1469-0691
DOI:10.1016/j.cmi.2025.06.009 This link opens in a new window
COBISS.SI-ID:244976643 This link opens in a new window
Publication date in RUL:08.04.2026
Views:193
Downloads:119
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Clinical microbiology and infection
Shortened title:Clin. microbiol. infect.
Publisher:Elsevier
ISSN:1469-0691
COBISS.SI-ID:58958081 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back